Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Bosutinib monohydrate
Brand Name Bosulif®
Payment Category Medicare Part D
Year Introduced 2012
Type of Drug Kinase inhibitor
Manufacturer Pfizer
Medical Affairs Questions (date verified) 800.438.1985
Coverage & Reimbursement Questions 866.706.2400

FDA-Approved Indication(s)

  • Indicated for the treatment of adult patients with 1) newly-diagnosed chronic phase Ph+ chronic mylelogenous leukemia (CML), and 2) chronic, accelerated, or blast phase CML with resistance or tolerance or intolerance to prior therapy. (12/20/17)

Approved Indication(s) with Orphan Drug Status Treatment of chronic myelogenous leukemia
ICD-10 Code(s) for Labeled Indication(s) Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission [C92.10] or in relapse [C92.12]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949